Stem cell therapy shows promise for managing fistulas.

The overview of systematic reviews indicates that stem cell therapy significantly improves clinical remission and fistula closure rates. The relative risk for clinical remission was 1.299, and for short- and long-term closure rates, it was 1.481 and 1.422, respectively. Importantly, safety analysis revealed no significant increase in adverse events, suggesting a favorable safety profile. The results recommend further high-quality studies to solidify these findings and potentially integrate stem cell therapy into standard fistula management practices.